DICE Therapeutics (NASDAQ: DICE – Get a review) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released Friday, Zacks.com reports.
According to Zacks, “DICE Therapeutics Inc. is a biopharmaceutical company. Its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE Therapeutics Inc. is based in SOUTH SAN FRANCISCO, CA.”
DICE stock traded at $0.87 during Friday’s session, hitting $17.56. 446,969 shares of the company were traded, compared to its average volume of 318,820. DICE Therapeutics has a 52-week low of $13.39 and a 52-week high of $40.50. The company has a debt ratio of 0.01, a current ratio of 29.77 and a quick ratio of 29.77. The company has a fifty-day simple moving average of $19.04 and a 200-day simple moving average of $22.25.
DICE Therapeutics (NASDAQ:DICE – Get Rating) last released quarterly earnings data on Monday, March 21. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.14. Analysts expect DICE Therapeutics to post earnings per share of -2.34 for the current fiscal year.
A number of hedge funds have been buying and selling stocks recently. New York State Common Retirement Fund increased its stake in DICE Therapeutics by 428.6% in Q1. The New York State Common Retirement Fund now owns 13,215 shares of the company worth $253,000 after purchasing an additional 10,715 shares during the period. Prospera Financial Services Inc bought a new position in DICE Therapeutics in Q1 worth approximately $39,000. Simplex Trading LLC bought a new position in DICE Therapeutics in Q1 worth approximately $207,000. Cutler Group LP bought a new position in DICE Therapeutics in Q1 worth approximately $279,000. Finally, BlackRock Inc. bought a new position in DICE Therapeutics in Q4 worth approximately $21,648,000. 82.91% of the shares are currently held by institutional investors.
About DICE Therapeutics (Get a rating)
DICE Therapeutics, Inc, a biopharmaceutical company, constructs various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its DELSCAPE platform is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.
Get a Free Copy of Zacks’ Research Report on DICE Therapeutics (DICE)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in DICE Therapeutics right now?
Before you consider DICE Therapeutics, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and DICE Therapeutics wasn’t on the list.
Although DICE Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here